Navigation Links
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
Date:3/4/2013

hase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013. AcelRx recently completed enrollment in a Phase 2 study for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command, and top-line results are expected in the second quarter of 2013.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the release of sufentanil NanoTab PCA System top-line clinical trial data, the release and anticipated timing of additional NanoTab System clinical trial data, the potential submission of an NDA for NanoTab System and the timing thereof, therapeutic and commercial potential of NanoTab System and the anticipated timing and therapeutic and commercial potential of other AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the ability of AcelRx Pharmaceuticals to successfully complete the clinical trials for the sufentanil NanoTab System, that fact that subsequent analyses of the top-line data may lead to different (including less favorable) interpretations of t
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. AcelRx Pharmaceuticals Provides Clinical Trial Updates
3. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
6. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
10. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
11. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... 2015 Memphis, TN: MedixSafe has retracted ... a new security reader named Guardian 2. The ... a new biometric scanner that significantly increases the ... the new biometric scanner provides fast and easy ... MedixSafe narcotics lockers with Vanguard technology ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... CARLOS, Calif., Nov. 7 Nektar,Therapeutics (Nasdaq: NKTR ... quarter that ended September 30, 2007. Revenue totaled ... to,$58.6 million in the third quarter of 2006. For ... revenue of $207.3 million,compared to $147.8 million in the ...
... Nov. 7 Rapid Pathogen Screening Inc.,(RPS) -- ... ocular,diseases -- announced today that the American Medical ... code that will cover the,RPS Adeno Detector(TM), effective ... code,for "Infectious agent antigen detection by immunoassay with ...
... 7 Mesa Laboratories,Inc. (Nasdaq: MLAB ) today reported ... and six months ended September 30, 2007. Highlights: ... * Second quarter net income increases 40% ... the second quarter of fiscal 2008, net sales increased 16 ...
... Corrective cardiac surgery is not to blame, study suggests , , ... in babies born with certain heart defects, new research shows. ... delay found in premature infants, the researchers added. , Babies ... developmental delays, but whether the delays were due to the ...
... This past weekend study,results on "Molecular Breast ... at the Nuclear Science Symposium and Medical,Imaging Conference ... laboratory study was to evaluate the performance of ... in which,the two imaging detectors are positioned on ...
... 7 Today, the release of,Emerging Answers 2007: ... Sexually Transmitted Disease, a report authored by Douglas,Kirby, ... once,again, that the $1.5 billion federal and state ... money., The report, commissioned by the National ...
Cached Medicine News:Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 2Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 3Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 4Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 5Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 6Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 7Health News:American Medical Association Clears Path for Adenoviral Conjunctivitis - 'Pink Eye' - Detector 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 3Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 4Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 5Health News:Heart Defects Can Delay Baby's Brain Development 2Health News:Heart Defects Can Delay Baby's Brain Development 3Health News:Heart Defects Can Delay Baby's Brain Development 4Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 2Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 3Health News:New Study - Same Verdict 2
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... derives its name from its first known ... The majority of PSA circulates bound to ... concentrations of PSA are elevated in patients ... and prostatitis [1-3]. In addition, PSA serum ...
... of Vision and Contrast Sensitivity. The ... and glare luminance levels for accurate ... with/without glare and background luminance Comply ... standards. All Light Levels Microprocessor Controlled ...
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Medicine Products: